CAJ | 학술논문

目的：检测细胞分裂周期蛋白25B（ CDC25B）在三阴性浸润性导管癌中的表达情况，分析其与三阴性浸润性导管癌预后的相关性。方法应用免疫组化染色技术检测92例三阴性浸润性导管癌石蜡标本中的 CDC25B 表达情况，并分析其与三阴性浸润性导管癌患者的年龄、TMN分期、淋巴结转移以及预后间的关系。结果三阴性浸润性导管癌中CDC25B 高表达率为39．1％（36／92）；CDC25 B高表达与腋窝淋巴结癌转移情况、TNM 分期、年龄、病理学类型、肿瘤大小均无统计学意义相关，CDC25B高表达组的总生存率、无病生存率均显著低于低表达组（ P＜0．05）。 Cox多因素分析结果显示CDC25B表达及腋窝淋巴结为无病生存率的独立预测因素。结论三阴性浸润性导管癌中CDC25B存在高表达，与乳腺癌的发展及预后有关，检测CDC25B对三阴性浸润性导管癌治疗及预后评估有一定参考意义。
목적：검측세포분렬주기단백25B（ CDC25B）재삼음성침윤성도관암중적표체정황，분석기여삼음성침윤성도관암예후적상관성。방법응용면역조화염색기술검측92례삼음성침윤성도관암석사표본중적 CDC25B 표체정황，병분석기여삼음성침윤성도관암환자적년령、TMN분기、림파결전이이급예후간적관계。결과삼음성침윤성도관암중CDC25B 고표체솔위39．1％（36／92）；CDC25 B고표체여액와림파결암전이정황、TNM 분기、년령、병이학류형、종류대소균무통계학의의상관，CDC25B고표체조적총생존솔、무병생존솔균현저저우저표체조（ P＜0．05）。 Cox다인소분석결과현시CDC25B표체급액와림파결위무병생존솔적독립예측인소。결론삼음성침윤성도관암중CDC25B존재고표체，여유선암적발전급예후유관，검측CDC25B대삼음성침윤성도관암치료급예후평고유일정삼고의의。
Objective To examine the expression of CDC25B and to evaluate its role as a prognostic marker in treating triple negative invasive ductal breast cancer.Method 92 cases of triple negative invasive ductal breast cancer were first subjected to immunohistochemical test for information of the expression of CDS25B.Its relationship with other variables such as the patient’s age, TNM staging, axillary lymph node metastasis, and prognosis were then analyzed.Findings In triple negative invasive ductal breast cancer, 39.1% of cases showed high expression of CDC25B (36/92).The expression of CDC25B was found to have no significant relationship with axillary lymph node metastasis, TNM staging, age, pathologic type or tumor size.The overall survival and disease-free survival rates of the high expression group was significantly lower than those of the low expression group (P<0.05).Cox multi-factor analysis showed that CDC25B expression and axillary lymph node status were independent prognostic factors of disease-free survival.Conclusion Over-expression of CDC25B was found in triple negative invasive ductal breast cancer and to correlate with the development and prognosis of breast cancer.The expression of CDC25B can serve as a significant prognostic marker in the treatment of breast cancer.